Asset
Luveltamab Tazevibulin
Sutro Biopharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05200364 | phase1 | terminated | 2022-03-22 | 2025-06-01 | Sutro Biopharma, Inc. | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer |
| NCT03748186 | phase1 | completed | 2019-02-01 | 2024-06-04 | Sutro Biopharma, Inc. | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers |
FDA applications (0)
This company has no applications containing this asset.